Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

被引：0
|
作者：
Song Mu
Zhiyu Tang
William Novotny
Manal Tawashi
Ta-Kai Li
Ying Ou
Srikumar Sahasranaman
机构：
[1] BeiGene USA,Clinical Pharmacology
[2] BeiGene USA,Clinical Development
[3] BeiGene USA,Clinical Operations
[4] BeiGene USA,Drug Safety and Pharmacovigilance
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
Clinical pharmacology; Clinical trials; Drug–drug interactions; Oncology; Pharmacokinetics and drug metabolism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：391 / 399
页数：8
相关论文
共 50 条
  • [31] In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
    Zhang, Heather
    Ou, Ying C.
    Su, Dan
    Wang, Fan
    Wang, Lai
    Sahasranaman, Srikumar
    Tang, Zhiyu
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (06):
  • [32] A NOVEL REVERSIBILE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR (BMS-986142) PROVIDES FAVORABLE SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC PROFILES IN HEALTHY SUBJECTS
    Lee, S. K.
    Xing, J.
    Catlett, I.
    Adamczyk, R.
    Griffies, A.
    Liu, A.
    Murthy, B.
    Nowak, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 256 - 256
  • [33] A CLINICAL STUDY TO ASSESS EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS (PK) OF NERATINIB (HKI-272), A PAN-ERBB RECEPTOR TYROSINE KINASE INHIBITOR, WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY SUBJECTS.
    Abbas, R.
    Hug, B.
    Leister, C.
    Sonnichsen, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S41 - S42
  • [34] Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
    Scheible, Holger
    Dyroff, Martin
    Seithel-Keuth, Annick
    Harrison-Moench, Eleanor
    Mammasse, Nadra
    Port, Andreas
    Bachmann, Angelika
    Dong, Jennifer
    van Lier, Jan Jaap
    Tracewell, William
    Mitchell, David
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2420 - 2430
  • [35] THE EFFECTS OF THE CYP3A INHIBITOR, ITRACONAZOLE, AND THE CYP3A INDUCER, RIFAMPIN, ON THE PHARMACOKINETICS OF THE MAO-B INHIBITOR, HT-3951, IN HEALTHY SUBJECTS.
    Charriez, C. M.
    Carpenter, D. J.
    Vuppala, P. K.
    Graham, M. A.
    Curtis, C.
    Hoffmann, I.
    Parsons, J. M.
    Ruckle, J.
    Perera, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S62 - S62
  • [36] The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions
    Karel, M. F. A.
    Tullemans, B. M. E.
    D'Italia, G.
    Lemmens, T. P.
    Claushuis, T. A. M.
    Kuijpers, M. J. E.
    Cosemans, J. M. E. M.
    THROMBOSIS RESEARCH, 2022, 212 : 72 - 80
  • [37] PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF BIIB091, A BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), IN HEALTHY VOLUNTEERS.
    Arefayene, M.
    Zhao, Y.
    Scaramozza, M.
    Hopkins, B.
    Bame, E.
    Franchimont, N.
    Naik, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S53 - S53
  • [38] EFFECT OF FOOD ON THE PHARMACOKINETICS OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB IN HEALTHY SUBJECTS.
    Lau, Y.
    Lin, T.
    Song, D.
    Gu, J.
    Yu, R.
    Joe, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S71 - S72
  • [39] Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
    Ucpinar, Sibel
    Smith, Patrick F.
    Long, Li
    Li, Fujun
    Yan, Hui
    Wadhwa, Jyoti
    Chu, Katherine A.
    Shu, Jin
    Nunn, Philip
    Li, Mengyao
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (07): : 1210 - 1219
  • [40] EVALUATION OF THE EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS ( PK) OF BOSUTINIB ( SKI-606), A DUAL INHIBITOR OF SRC AND ABL TYROSINE KINASES, WHEN ADMINISTERED CONCOMITANTLY TO HEALTHY SUBJECTS.
    Abbas, R.
    Boni, J.
    Hug, B.
    Leister, C.
    Burns, J.
    Sonnichsen, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S87 - S87
12345